Crucial Roles of Sp1 and Epigenetic Modifications in the Regulation of the CLDN4 Promoter in Ovarian Cancer Cells*

Claudins form a large family of tight junction proteins that have essential roles in the control of paracellular ion flux and the maintenance of cell polarity. Many studies have shown that several claudin family members are abnormally expressed in various cancers. In particular, CLDN4 (encoding claudin-4) is overexpressed in ovarian cancer. However, although CLDN4 overexpression is well established, the mechanisms responsible for this abnormal regulation remain unknown. In the present study, we delineate a small region of the CLDN4 promoter critical for its expression. This region contains two Sp1 sites, both of which are required for promoter activity. However, because of the ubiquitous expression of Sp1, these sites, although necessary, are not sufficient to explain the patterns of gene expression of CLDN4 in various ovarian tissues. We show that the CLDN4 promoter is further controlled by epigenetic modifications of the Sp1-containing critical promoter region. Cells that overexpress CLDN4 exhibit low DNA methylation and high histone H3 acetylation of the critical CLDN4 promoter region, and the reverse is observed in cells that do not express CLDN4. Moreover, the CLDN4-negative cells can be induced to express CLDN4 through treatment with demethylating and/or acetylating agents. Because CLDN4 is elevated in a large fraction of ovarian cancer, the mechanism leading to deregulation may represent a general pathway in ovarian tumorigenesis and may lead to novel strategies for therapy and an overall better understanding of the biology of this disease.

[1]  M. Russo,et al.  Oestrogens and selective oestrogen receptor (ER) modulators regulate EGF receptor gene expression through human ER α and β subtypes via an Sp1 site , 2003, Oncogene.

[2]  Biaoyang Lin,et al.  Proteins Associated with Cisplatin Resistance in Ovarian Cancer Cells Identified by Quantitative Proteomic Technology and Integrated with mRNA Expression Levels*S , 2006, Molecular & Cellular Proteomics.

[3]  Y. DeClerck,et al.  Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases. , 1997, Gynecologic Oncology.

[4]  Yinhua Yu,et al.  Potential markers that complement expression of CA125 in epithelial ovarian cancer. , 2005, Gynecologic oncology.

[5]  D. Butcher,et al.  Characterization of functional elements in the neurofibromatosis (NF1) proximal promoter region , 2004, Oncogene.

[6]  P. Morin,et al.  Phosphorylation of Claudin-3 at Threonine 192 by cAMP-dependent Protein Kinase Regulates Tight Junction Barrier Function in Ovarian Cancer Cells* , 2005, Journal of Biological Chemistry.

[7]  Erming Tian,et al.  Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy , 2004, International journal of cancer.

[8]  P. Datta,et al.  Stability of the Sp3-DNA complex is promoter-specific: Sp3 efficiently competes with Sp1 for binding to promoters containing multiple Sp-sites. , 2003, Nucleic acids research.

[9]  S. Clark,et al.  Transcriptional Gene Silencing Promotes DNA Hypermethylation through a Sequential Change in Chromatin Modifications in Cancer Cells , 2004, Cancer Research.

[10]  T. Yamashita,et al.  Thr203 of claudin-1, a putative phosphorylation site for MAP kinase, is required to promote the barrier function of tight junctions. , 2003, Experimental cell research.

[11]  A. Gartel,et al.  Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  G. Riggins,et al.  Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. , 2000, Cancer research.

[13]  T. Sakai,et al.  Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. , 1999, Cancer research.

[14]  M. Beato,et al.  An inhibitor domain in Sp3 regulates its glutamine‐rich activation domains. , 1996, The EMBO journal.

[15]  E. Siegel,et al.  Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. , 2005, Cancer research.

[16]  C. Plass,et al.  Methylation of Adjacent CpG Sites Affects Sp1/Sp3 Binding and Activity in the p21Cip1 Promoter , 2003, Molecular and Cellular Biology.

[17]  Amy P N Skubitz,et al.  Differential gene expression in ovarian carcinoma: identification of potential biomarkers. , 2004, The American journal of pathology.

[18]  Robert C. Bast,et al.  Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis , 2004, Clinical Cancer Research.

[19]  P. Argani,et al.  Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast , 2003, Oncogene.

[20]  W. Lancaster,et al.  Organotypic culture of human ovarian surface epithelial cells: A potential model for ovarian carcinogenesis , 1998, In Vitro Cellular & Developmental Biology - Animal.

[21]  S. Baylin,et al.  DNA methylation and gene silencing in cancer , 2005, Nature Clinical Practice Oncology.

[22]  M. Brännström,et al.  Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours , 2006, International journal of cancer.

[23]  Shoichiro Tsukita,et al.  Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail , 2003, Journal of Cell Science.

[24]  M. Dufau,et al.  Coordinated Changes in DNA Methylation and Histone Modifications Regulate Silencing/Derepression of Luteinizing Hormone Receptor Gene Transcription , 2005, Molecular and Cellular Biology.

[25]  A. Gartel,et al.  Sp1 and Sp3 activate p21 (WAF1/CIP1) gene transcription in the Caco-2 colon adenocarcinoma cell line , 2000, Oncogene.

[26]  Shoichiro Tsukita,et al.  Multifunctional strands in tight junctions , 2001, Nature Reviews Molecular Cell Biology.

[27]  J. Katahira,et al.  Clostridium perfringens Enterotoxin Utilizes Two Structurally Related Membrane Proteins as Functional Receptors in Vivo * , 1997, The Journal of Biological Chemistry.

[28]  P. Morin,et al.  Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. , 2005, Cancer research.

[29]  T. Tsuchiya,et al.  Induction of claudin-4 by nonsteroidal anti-inflammatory drugs and its contribution to their chemopreventive effect. , 2005, Cancer research.

[30]  G. Stein,et al.  Sp1 trans-activation of cell cycle regulated promoters is selectively repressed by Sp3. , 1995, Biochemistry.

[31]  Kathleen R. Cho,et al.  Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  Brad Saville,et al.  Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor α and SP proteins , 2004, Oncogene.

[33]  G. Deng,et al.  Promoter methylation inhibits APC gene expression by causing changes in chromatin conformation and interfering with the binding of transcription factor CCAAT-binding factor. , 2004, Cancer research.

[34]  S. Tapscott,et al.  Two domains of MyoD mediate transcriptional activation of genes in repressive chromatin: a mechanism for lineage determination in myogenesis. , 1997, Genes & development.

[35]  P. Morin,et al.  Claudin proteins in human cancer: promising new targets for diagnosis and therapy. , 2005, Cancer research.